Search Results - "YAMADA, S. Diane"

Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts by Eckert, Mark A., Coscia, Fabian, Chryplewicz, Agnieszka, Chang, Jae Won, Hernandez, Kyle M., Pan, Shawn, Tienda, Samantha M., Nahotko, Dominik A., Li, Gang, Blaženović, Ivana, Lastra, Ricardo R., Curtis, Marion, Yamada, S. Diane, Perets, Ruth, McGregor, Stephanie M., Andrade, Jorge, Fiehn, Oliver, Moellering, Raymond E., Mann, Matthias, Lengyel, Ernst

“…High-grade serous carcinoma has a poor prognosis, owing primarily to its early dissemination throughout the abdominal cavity. Genomic and proteomic approaches…”
Get full text

Fibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis by Curtis, Marion, Kenny, Hilary A., Ashcroft, Bradley, Mukherjee, Abir, Johnson, Alyssa, Zhang, Yilin, Helou, Ynes, Batlle, Raquel, Liu, Xiaojing, Gutierrez, Nuria, Gao, Xia, Yamada, S. Diane, Lastra, Ricardo, Montag, Anthony, Ahsan, Nagib, Locasale, Jason W., Salomon, Arthur R., Nebreda, Angel R., Lengyel, Ernst

“…Successful metastasis requires the co-evolution of stromal and cancer cells. We used stable isotope labeling of amino acids in cell culture coupled with…”
Get full text

Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth by Nieman, Kristin M, Kenny, Hilary A, Penicka, Carla V, Ladanyi, Andras, Buell-Gutbrod, Rebecca, Zillhardt, Marion R, Romero, Iris L, Carey, Mark S, Mills, Gordon B, Hotamisligil, Gökhan S, Yamada, S Diane, Peter, Marcus E, Gwin, Katja, Lengyel, Ernst

“…Ovarian tumors preferentially metastasize to the omentum, a peritoneal fat layer. This report proposes that the reasons for this predilection stem from the…”
Get full text

Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion by Kenny, Hilary A, Chiang, Chun-Yi, White, Erin A, Schryver, Elizabeth M, Habis, Mohammed, Romero, Iris L, Ladanyi, Andras, Penicka, Carla V, George, Joshy, Matlin, Karl, Montag, Anthony, Wroblewski, Kristen, Yamada, S Diane, Mazar, Andrew P, Bowtell, David, Lengyel, Ernst

“…Ovarian cancer (OvCa) metastasizes to organs in the abdominal cavity, such as the omentum, which are covered by a single layer of mesothelial cells…”
Get full text

Relationship of Type II Diabetes and Metformin Use to Ovarian Cancer Progression, Survival, and Chemosensitivity by Romero, Iris L, McCormick, Anna, McEwen, Kelsey A, Park, SeoYoung, Karrison, Theodore, Yamada, S Diane, Pannain, Silvana, Lengyel, Ernst

“…OBJECTIVE:To estimate whether metformin use by ovarian cancer patients with type II diabetes was associated with improved survival. METHODS:We reviewed the…”
Get full text

Genomics of Ovarian Cancer Progression Reveals Diverse Metastatic Trajectories Including Intraepithelial Metastasis to the Fallopian Tube by Eckert, Mark A, Pan, Shawn, Hernandez, Kyle M, Loth, Rachel M, Andrade, Jorge, Volchenboum, Samuel L, Faber, Pieter, Montag, Anthony, Lastra, Ricardo, Peter, Marcus E, Yamada, S Diane, Lengyel, Ernst

“…Accumulating evidence has supported the fallopian tube rather than the ovary as the origin for high-grade serous ovarian cancer (HGSOC). To understand the…”
Get more information

Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study by Farley, John, Prof, Brady, William E, PhD, Vathipadiekal, Vinod, PhD, Lankes, Heather A, PhD, Coleman, Robert, Prof, Morgan, Mark A, Prof, Mannel, Robert, Prof, Yamada, S Diane, Prof, Mutch, David, Prof, Rodgers, William H, Prof, Birrer, Michael, MD, Gershenson, David M, MD

“…Summary Background Low-grade serous carcinoma of the ovary is chemoresistant but mutations in the MAPK pathway could be targeted to control tumour growth. We…”
Get full text

The effect of treatment time in locally advanced cervical cancer in the era of concurrent chemoradiotherapy by Song, Suisui, Rudra, Sonali, Hasselle, Michael D., Dorn, Paige L., Mell, Loren K., Mundt, Arno J., Yamada, S. Diane, Lee, Nita K., Hasan, Yasmin

“…BACKGROUND: This study sought to determine if treatment time impacts pelvic failure (PF), distant failure (DF), or disease‐specific mortality (DSM) in patients…”
Get full text

Gaps in patient-physician communication at the time of malignant bowel obstruction from recurrent gynecologic cancer: a qualitative study by Hoppenot, Claire, Hlubocky, Fay J., Chor, Julie, Yamada, S. Diane, Lee, Nita K.

“…Purpose We sought to investigate the patient and physician approaches to malignant bowel obstruction (MBO) due to recurrent gynecologic cancer by (1) comparing…”
Get full text

International Gynecologic Cancer Society (IGCS) 2018: Meeting report by Duska, Linda R., Suh, Dong Hoon, Wilson, Michelle, Diane Yamada, S.

Get full text

Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199 by Sherman, Mark E, Piedmonte, Marion, Mai, Phuong L, Ioffe, Olga B, Ronnett, Brigitte M, Van Le, Linda, Ivanov, Iouri, Bell, Maria C, Blank, Stephanie V, DiSilvestro, Paul, Hamilton, Chad A, Tewari, Krishnansu S, Wakeley, Katie, Kauff, Noah D, Yamada, S Diane, Rodriguez, Gustavo, Skates, Steven J, Alberts, David S, Walker, Joan L, Minasian, Lori, Lu, Karen, Greene, Mark H

“…Risk-reducing salpingo-oophorectomy (RRSO) lowers mortality from ovarian/tubal and breast cancers among BRCA1/2 mutation carriers. Uncertainties persist…”
Get full text

Activity of Sorafenib in Recurrent Ovarian Cancer and Primary Peritoneal Carcinomatosis: A Gynecologic Oncology Group Trial by MATEI, Daniela, SILL, Michael W, PETRICOIN, Emanuel F, BIRRER, Michael J, LANKES, Heather A, DEGEEST, Koen, BRISTOW, Robert E, MUTCH, David, YAMADA, S. Diane, COHN, David, CALVERT, Valerie, FARLEY, John

“…PURPOSE Sorafenib is a kinase inhibitor targeting Raf and other kinases (ie, vascular endothelial growth factor receptor [VEGFR], platelet-derived growth…”
Get full text

Geospatial patterns of access to self-care resources for obesity among endometrial cancer survivors in a high poverty urban community by Ross, Jerlinda G.C., Escamilla, Veronica, Lee, Nita Karnik, Diane Yamada, S., Lindau, Stacy Tessler

“…To examine endometrial cancer survivors' access to recommended obesity-related self-care resources. Participants included women treated 2010–2015 for…”
Get full text

Differences in Sociodemographic Disparities Between Patients Undergoing Surgery for Advanced Colorectal or Ovarian Cancer by Goldberg, Ellen M., Berger, Yaniv, Sood, Divya, Kurnit, Katherine C., Kim, Josephine S., Lee, Nita K., Yamada, S. Diane, Turaga, Kiran K., Eng, Oliver S.

“…Background Cytoreductive surgery (CRS) for ovarian cancer with peritoneal metastases (OPM) is an established treatment, yet access-related racial and…”
Get full text

Efficacy and safety of bevacizumab in recurrent sex cord‐stromal ovarian tumors: Results of a phase 2 trial of the Gynecologic Oncology Group by Brown, Jubilee, Brady, William E., Schink, Julian, Le, Linda, Leitao, Mario, Yamada, S. Diane, Geest, Koen, Gershenson, David M.

“…BACKGROUND The Gynecologic Oncology Group conducted this phase 2 trial to estimate the antitumor activity of bevacizumab and to determine the nature and degree…”
Get full text

Primary gynecologic lymphoma when diagnosed by a gynecologist: A case series by Lamacki, Alexandra J., Montag, Caroline, Kertowidjojo, Elizabeth, Diane Yamada, S., Kurnit, Katherine C.

“…Primary lymphomas of the gynecologic tract are a rare pathology that may present with typical gynecologic symptoms. Unlike other gynecologic malignancies,…”
Get full text

Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study by Gotlieb, Walter H, Dr, Amant, Frederic, MD, Advani, Suresh, MD, Goswami, Chanchal, MD, Hirte, Hal, MD, Provencher, Diane, MD, Somani, Naresh, MD, Yamada, S Diane, MD, Tamby, Jean-Francois, MD, Vergote, Ignace, MD

“…Summary Background Targeting of VEGF is a potential therapeutic option in patients with malignant ovarian ascites. We present the final results of a…”
Get full text

Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: A Gynecologic Oncology Group study by Alvarez, Edwin A, Brady, William E, Walker, Joan L, Rotmensch, Jacob, Zhou, Xun C, Kendrick, James E, Yamada, S. Diane, Schilder, Jeanne M, Cohn, David E, Harrison, Charles R, Moore, Kathleen N, Aghajanian, Carol

“…Abstract Objective This two-stage phase II study was designed to assess the activity of the combination of temsirolimus and bevacizumab in patients with…”
Get full text

ASO Visual Abstract: Differences in Sociodemographic Disparities in Patients Undergoing Surgery for Advanced Colorectal and Ovarian Cancer by Goldberg, Ellen M., Berger, Yaniv, Sood, Divya, Kurnit, Katherine C., Kim, Josephine S., Lee, Nita K., Yamada, S. Diane, Turaga, Kiran K., Eng, Oliver S.

Get full text

Foretinib (GSK1363089), an Orally Available Multikinase Inhibitor of c-Met and VEGFR-2, Blocks Proliferation, Induces Anoikis, and Impairs Ovarian Cancer Metastasis by ZILLHARDT, Marion, PARK, Sun-Mi, ROMERO, Iris L, SAWADA, Kenjiro, MONTAG, Anthony, KRAUSZ, Thomas, YAMADA, S. Diane, PETER, Marcus E, LENGYEL, Ernst

“…Currently, there are no approved targeted therapies for the treatment of ovarian cancer, despite the fact that it is the most lethal gynecological malignancy…”
Get full text